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Abstract 
Both pharmacological and behavioral interventions are widely accepted as methods to manage 
ADHD.  For emerging adults with ADHD, low rates of treatment adherence preclude individuals 
from the long-term health benefits of evidence-based treatments, and instead leave them 
vulnerable to negative outcomes associated with the disorder.  Despite these concerns, little is 
known about factors impacting treatment adherence in the adult ADHD population.  The present 
study aimed to address limitations to the extant literature through examination of alterable and 
inalterable factors related to treatment adherence to psychopharmacological treatments in college 
students with ADHD.  Data collected through self-report ratings and direct testing was analyzed 
for 94 college students with a diagnosis of ADHD who received medication treatments.  Results 
indicated that none of the identified factors were predictive of treatment adherence in this 
population.  Relationships between the latent variables (i.e., medication tolerability, attitudes 
towards treatment), and treatment adherence were also not statistically significant.  Findings 
suggest that factors related to treatment adherence for the college population likely differ from 
those for the rest of the ADHD population.  Additionally, findings demonstrate the necessity for 
additional research on treatment adherence to psychopharmacological treatments in emerging 
adults with ADHD to better understand and improve trends in adherence across the lifespan. 
 
 
 
 
 
 
  
2 
CHAPTER 1 
Introduction 
The worldwide point prevalence of attention-deficit/hyperactivity disorder (ADHD) is 
estimated at 5.3-7.1% (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007; Willcutt, 2012).  
In the United States, the rate of childhood ADHD is estimated at 5-11% (Centers for Disease 
Control, 2013) and adult ADHD at 4.4% (Kessler et al., 2006).  Although ADHD emerges during 
early childhood, research has documented the persistence of ADHD into adolescence and 
adulthood (Bramham et al., 2012; Fischer, Barkley, Smallish, & Fletcher, 2005; Goodman, 2007; 
Hechtman, 2017; Hechtman et al., 2016).  The Diagnostic and Statistical Manual of Mental 
Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013) characterizes adult ADHD 
by five or more symptoms of hyperactivity/impulsivity or inattention associated with significant 
impairments in life functioning. 
The core symptoms of ADHD can be highly impairing for individuals with the disorder 
as symptomatic behaviors interfere with multiple aspects of an individual’s functioning (e.g., 
social, cognitive, occupational).  More specifically, ADHD is associated with academic 
impairments (DuPaul, Weyandt, O’Dell, & Varejao, 2009), social skills difficulties (Cordier, 
Bundy, Hocking, & Einfeld, 2010; DuPaul, McGoey, Eckert, & VanBrakle, 2001; Normand et 
al., 2011), and increased risk-taking behaviors that can lead to extremely detrimental health and 
educational outcomes (e.g., school dropout, car accidents, alcohol and drug use, psychiatric 
disorders, criminal activity; Barkley, Cook, Dulcan, Campbell, & Prior, 2002; Barkley, Fischer, 
Smallish, & Fletcher, 2006; Biederman et al., 2007; Biederman et al., 2008; Hechtman, 2017; 
Hechtman et al., 2016; Roy et al., 2016).  Although symptoms of adult ADHD may look slightly 
different from the manifestation of the disorder in childhood (e.g., shift towards inattentive 
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clinical presentation vs. hyperactivity-impulsivity clinical presentation, decreased severity of 
behavioral symptoms; Bramham et al., 2012; Fischer, Barkley, Smallish, & Fletcher, 2005), 
ADHD in adults leads to many similar negative outcomes and significant impairments in school, 
work, social, and home environments (Brown, 2000).   
College Students with ADHD 
Although there has been a significant amount of research on children and adults with 
ADHD, relatively less is known about the college population.  Due to significant impairments in 
functioning, only a small percentage of individuals with ADHD attend college, and from that 
group, only about 5% actually graduate (Barkley, 2002; Hechtman, 2017; Hechtman et al., 
2016).  Because such a small portion of students with this disorder pursue and complete a degree 
in higher education, it is likely that this group of individuals has a set of characteristics that differ 
from the rest of the population with ADHD.  It is important to understand this subset of the 
population in order to target interventions and treatments to best promote positive post-secondary 
school outcomes. 
Despite deficits in multiple functional domains, rates of college students with ADHD 
continue to rise (Gaddy, 2008).  It is estimated that between 2-8% of college students have a 
diagnosis of ADHD (DuPaul, Weyandt, O’Dell, & Varejao, 2009), with more recent reports 
indicating that approximately 5.9% of first-year college students self-report a diagnosis of 
ADHD (Eagan et al., 2014).  Among the population of college students with disabilities, about 
25% are diagnosed with ADHD (DuPaul, Weyandt, O’Dell, & Varejao, 2009).  Because 
symptoms of ADHD may cause impairments in behaviors essential for successful functioning in 
adulthood (e.g., self-regulation, attention), emerging adulthood (i.e., college age) is a particularly 
consequential time for intervention and symptom management (Fleming & McMahon, 2012).  
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The college environment poses unique challenges (e.g., loss of structure and parental support, 
increased emphasis on executive functioning) for students with ADHD that may interfere with 
treatment and positive outcomes.  These challenges represent a less than ideal environment for 
individuals with ADHD because they emphasize skills (e.g., self-regulation, executive 
functioning) that are specifically impaired by the disorder (American Psychiatric Association, 
2013).  Further, because the neurological systems of college students are still maturing, the self-
regulation skills of college students may be underdeveloped and insufficient to respond 
appropriately to these heightened demands (Fleming & McMahon, 2012). 
Based on these challenges, college students with ADHD are at risk for experiencing 
academic difficulty and failure (for review, see DuPaul et al., 2009).  Specifically, college 
students with ADHD are at risk for lower academic performance (Heiligenstein, Guenther, Levy, 
Savino, & Fulwiler, 1999; Weyandt & DuPaul, 2006) and have more academic problems and 
lower GPAs than their healthy peers (Gormley et al., 2015; Gormley et al., 2016; Hellingstein et 
al., 1999).  College students with ADHD are also at an increased risk for engaging in risk-taking 
behaviors (e.g., risky sexual behaviors, substance abuse; Charach, Yeung, Climans, & Lillie, 
2010; Flory, Molina, Pelham, Gnagy, & Smith, 2006; Molina et al., 2013).  Additional social, 
occupational, emotional, and other functional impairments may also have profound impacts on 
both short- and long-term outcomes (Arnold, Hodgkins, Caci, Kahle, & Young, 2015; Fleming & 
McMahon, 2012; Weyandt et al., 2013).  
Treatments for ADHD 
To protect against these negative outcomes, ADHD can be effectively managed with 
pharmacological and/or behavioral treatments (American Academy of Pediatrics [AAP], 2011).  
Individuals who are treated for their ADHD tend to have better outcomes (e.g., social, 
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educational, occupational, risk taking) than those who are not treated (Arnold et al., 2015; Shaw 
et al., 2012).  Both pharmacological and behavioral interventions are widely accepted as methods 
to manage ADHD, and can help to promote positive functioning in a variety of areas (AAP, 
2011; He & Antshel, 2017; Wilens et al., 1998; Wilens et al., 2001).  Despite the benefits of each 
form of treatment, however, each treatment modality is associated with various risks and 
barriers.  Best practice treatment should maximize benefits and minimize harm for each 
individual.  Therefore, in order to optimize outcomes, it is important to carefully evaluate the 
costs and benefits of each treatment modality. 
Psychopharmacological Treatment.  The most frequently recommended treatment for 
children (Greenhill, Pliszka, & Dulcan, 2002; Plizka, 2007; Subcommittee on Attention 
Deficit/Hyperactivity Disorder, 2011) and adults (for reviews, see Prince, Wilens, Spencer, & 
Biederman, 2015; Wilens, Morrison, & Prince, 2011) with ADHD is psychopharmacological 
therapy.  In 2007, over 2.7 million children between the ages of 4 to 17 were receiving 
pharmacological treatment for ADHD (Visser et al., 2014).  Medication treatment for ADHD 
includes stimulant medications, specifically central nervous system (CNS) stimulant medications 
such as methlyphenidate, dextroamphetamine, and mixed amphetamines (Levine, 2005; Stolzer, 
2009).  For the pharmacological treatment of adults with ADHD, the approved medication 
classes include atomoxetine (ATMX), amphetamine (AMPH), and methylphenidate (MPH).  
These medications decrease symptoms of inattention, impulsivity, and hyperactivity (Connor, 
2006; DuPaul et al., 2012; Heiligenstein, Johnston, & Nielsen, 1996; Northup, Gulley, Edwards, 
& Fountain, 2001; Peterson et al., 2009; Southammakosane & Schmitz, 2015, Prince et al., 
2015), and individuals who are treated with medication have improvements in disruptive 
behavior, academic achievement, and peer relations (Connor, 2006; DuPaul et al., 2012; Jensen 
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et al., 2007; Molina et al., 2009; MTA Cooperative Group, 1999; MTA Cooperative Group, 
2004).  Further, the use of stimulant medications helps to protect individuals with ADHD from 
problems with drug abuse, learning difficulties, social dysfunction, and comorbid 
psychopathology in adulthood (Biederman et al., 2005; Goksoyr & Nottestad, 2008).   
Despite the many benefits of pharmacological treatment, there are also risks associated 
with this type of intervention for ADHD.  Of particular prominence are adverse side-effects 
associated with psychostimulant medication including reduction in appetite, emotional labiality, 
difficulty sleeping, and other deleterious symptoms (Fleming & McMahon, 2012). These side-
effects can be extremely harmful and unpleasant, creating their own challenges for functioning.  
In addition to negative physical reactions, there are also social consequences associated with 
psychopharmacological treatment.  Due to stigma surrounding the disorder, many individuals 
(e.g., parents, teachers, healthcare professionals, public) have incorrect knowledge about ADHD 
treatment and falsely believe that ADHD medication is used for unsuitable reasons (Moldavsky 
& Saval, 2013).  Regardless of the well-established research supporting the use of these 
medications, these fallacious beliefs may increase stigma towards those being treated with 
medication for the disorder.  Additionally, particularly in the college population, there is a risk of 
stimulant misuse or diversion, which could also influence the health of individuals without 
ADHD (Fleming & McMahon, 2012). 
Behavioral Treatment.  Due to barriers associated with ADHD medications (e.g., 
adverse side-effects, stigma), behavioral treatments are also used to manage ADHD symptoms 
and have been suggested to be highly effective (AAP, 2011; Fabiano et al., 2009; Kaiser & 
Pfiffner, 2001).  Given the unique and complimentary strengths of each treatment type, it is 
recommended that psychosocial treatments and psychopharmacological treatments are used in 
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combination (Arnold, Hodgkins, Caci, Kahle, & Young, 2015; Jensen et al., 2001); however, if 
families opt for a single method treatment modality, there are a variety of evidence-based 
behavioral interventions used for treatment for ADHD.  For children, psychosocial treatment 
includes parent and teacher training (Evans, Owens, Wymbs, & Ray, 2018 Pelham & Fabiano, 
2008), classroom management, peer intervention, organizational training, combined behavioral 
management interventions, (Evans et al., 2018), cognitive behavioral therapy (Prevatt & Yelland, 
2013), and neurocognitive training (Chacko et al., 2013; Fabiano, Schatz, Aloe, Chacko, & 
Chronis-Tuscano, 2015; Rapport et al., 2013).  Interventions for adults with ADHD include 
group (e.g., dialectical behavioral therapy, metacognitive therapy, cognitive-behavioral therapy 
[CBT], mindfulness meditation training) and individually based (e.g., CBT, coaching) treatments 
(He & Antshel, 2017; Prevatt & Yelland, 2013; Safren et al., 2010; Solanto et al., 2010).  
Psychosocial interventions for adults with ADHD are still in the early stages of development; 
however, there is a growing body of evidence supporting the efficacy of these treatments for 
adult ADHD (for review, see He & Antshel, 2017).  By using behavioral interventions rather 
than medication, the risks of adverse physical side-effects are eliminated and individuals are also 
taught behavioral skills that may generalize across settings in ways that medication effects do 
not.  Additionally, although the research has not fully evaluated long-term consequences for 
adults, for children, psychosocial treatments may have less social consequences and may be 
perceived as more acceptable than psychopharmacological treatments (Krain, Kendall, & Power, 
2005).   
Although behavioral treatments may offset some of the negative consequences of 
pharmacological treatment, significant challenges are also associated with the implementation of 
psychosocial treatment.  For example, behavior therapies require a great deal of resources and 
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time commitment (AAP, 2011; Van Cleave & Leslie, 2008).  Additionally, because adolescents 
and emerging adults have a tendency to resist treatment and deny impairment, as individuals 
begin to make independent treatment decisions, they may be less willing to engage in behavioral 
interventions (Barkley, Edwards, Laneri, Fletcher, & Metevia, 2001; Biddle, Donovan, Sharp, & 
Gunnell, 2007; Fischer, Barkley, Fletcher, & Smallish, 1993).  Other factors such as therapeutic 
alliance, affordability, scheduling, cultural barriers, and stigma may also influence appropriate 
psychosocial treatment usage (Gearing et al., 2014).  Perhaps most importantly, although 
evidence supports the use of psychosocial treatments with certain childhood populations, there 
are still challenges associated with effectively implementing these techniques in practical 
settings, particularly due to limitations in the understanding of the utility of these interventions 
across all populations (e.g., varying demographic characteristics; Evans et al., 2018).  For 
adolescents and adults, due to methodological limitations in the literature and the large 
variability in types and intensities of psychosocial interventions it is difficult to make firm 
conclusions about the overall effectiveness of psychosocial treatments in older populations 
(Evans et al., 2018; Fabiano et al., 2015; He & Antshel, 2017). 
Combined Treatments.  Best practice treatment for children with ADHD is a 
combination of pharmacological and behavioral therapy (Arnold et al., 2015; Jensen et al., 2001).  
For adults, combined CBT and medication interventions have shown promise in reducing ADHD 
symptoms; however, due to a dearth of studies in this area, it is unclear to what extent combined 
treatments were superior to individual treatments in this population (Rostain & Ramsay, 2006; 
Safren et al., 2005).  Because many adults do not respond to or experience full symptom relief 
from medication, it is recommended that pharmacological treatment is supplemented with 
psychosocial interventions (Dulcan & Benson, 1997; Wender, 1998; Wilens, Biederman, & 
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Spencer, 1998; Wilens et al., 2001).  Despite this recommendation, however, limited empirical 
research has evaluated the benefits of combined treatments for adults.  Due to the complex and 
individualized components of combined treatments, the exact dosage or methods of therapy can 
be difficult to measure. 
Regardless of these limitations, in addition to possible positive treatment effects, 
evidence suggests that the use of combined therapy can lead to greater treatment acceptability 
(Pelham & Gnagy, 1999).  Increased acceptability is potentially associated with treatment 
effectiveness and/or required dosage (e.g., each individual treatment component typically 
administered in lower doses), thus reducing the risk of adverse side-effects associated with 
isolated pharmacological or psychosocial therapies, as side-effects typically correlate with 
treatment dosage or intensity.  Combined treatments may more comprehensively treat symptoms 
of ADHD by minimizing many of the shortcomings of each individualized treatment (e.g., 
psychopharmacology, psychosocial).  Unfortunately, combined therapies may not fully eliminate 
many of the negative aspects of treatment associated with each treatment type (e.g., medication 
side-effects, resources, stigma).  Finally, there can be a great degree of variability in the 
topography of combined treatments, which can lead to differences in treatment effectiveness.  
Treatment Adherence 
Regardless of the potential harm associated with the treatments for ADHD, in general, 
the benefits of evidence-based treatments outweigh the risks and can assuage or eliminate many 
of the deleterious outcomes associated with ADHD (AAP, 2011; He & Antshel, 2017; Kaiser & 
Pfiffner, 2011; Vaughan, March, & Kratochvil, 2012; Wilens et al., 2001).  Despite the efficacy 
of these treatments, many individuals do not receive proper or any treatment for their ADHD 
(Corkum et al., 2013).  Families are more willing to pursue recommendations for medication-
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based treatment than psychosocially based treatment, but treatment initiation rates are still only 
estimated to be around 65% (MacNaughton & Rodrigue, 2001).  Among those who do initiate 
treatment, adherence over a long period of time is extremely limited (Corkum et al., 2013).  
Treatment adherence is conceptualized as the extent to which a person’s behavior follows the 
agreed upon recommendations from the health care provider (e.g., dose, frequency, duration; 
Sabate, 2003; Treuer, Mendez, Montgomery, & Wu, 2016).  For children and adults with 
ADHD, the prevalence of medication nonadherence or discontinuation has been estimated 
between 13.2% to 64% (for review, see Adler, Nierenberg, & Andrew, 2010).  According to 
some reports, adherence to medication is estimated to decrease to rates of 61% adherence over a 
5-year period (Corkum, Rimer, & Schachar, 1999; Faraone, Biederman, & Zimmerman, 2007; 
Gau et al., 2008; Thiruchelvam, Charach, & Schachar, 2001).  Other estimates of adherence 
report persistence rates are as low as 15% following one year of treatment (Marcus, Wan, 
Kemner, & Olfson, 2005).  Due to the variability in treatment type and measurement, even less is 
known about adherence to psychosocial treatments and the resultant outcomes, but it is likely 
that the efficacy of psychosocial treatments is greatly reduced when treatment guidelines are not 
appropriately implemented or adhered to (Gearing, Townsend, Elkins, El-Bassel, & Ostreberg, 
2014).  Research has demonstrated that regardless of treatment type (e.g. pharmacological, 
behavioral, stimulant), individuals with ADHD, in particular, have especially poor treatment 
adherence (Hong et al., 2013). 
Proper treatment adherence is associated with many benefits including improvements in 
psychological functioning, overall quality of health, and quality of life (Drotar et al., 2007; 
Ekberg et al., 2007; Fredericks et al., 2008; Hommel, Davis, & Baladasso, 2008).  Additionally, 
from a broader public health perspective, treatment adherence can reduce medical expenditure 
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and disease burden (Krueger, Berger, & Felkey, 2005).  In contrast, any deviation from the 
health care provider’s recommendations (e.g., altered dosage, termination of treatment) is 
defined as non-adherence.  Low medication adherence impacts multiple aspects of treatment 
including symptom severity and relapse as well as a clinician’s ability to determine treatment 
efficacy and appropriate dosage adjustments (Adler, & Nierenberg, 2010; Safren, Duran, Yovel, 
Perlman, & Sprich, 2007).  Non-adherence to pharmacological and behavioral treatments is 
associated with increased health care needs and occupational and academic impairments, placing 
a burden on the individual as well as society as a whole (Gearing et al., 2014; Lehane, & 
Mccarthy, 2009; National Council on Patient Information and Education, 2004; Pai & Drotar, 
2010).  Without proper adherence, clinical decision-making is compromised, and individuals do 
not receive the benefits of evidence-based treatments.  Because ADHD is a chronic disorder, 
individuals must demonstrate treatment adherence for long periods of time in order to fully 
benefit from positive treatment effects and continuously prevent negative outcomes (Ahmed & 
Aslani, 2013). 
Despite these serious health concerns, factors related to treatment adherence for children 
with ADHD remains an under-researched topic.  Research on adults with the disorder is even 
more limited, with only one expert opinion article providing reasoning for treatment 
discontinuation (i.e., adverse-side effects, suboptimal response rates, social stigma, and dosing 
inconvenience; Ahmed & Aslani, 2013; Gajria et al., 2014).  Throughout the research literature, 
there is a lack of standardization of the definitions and measurements of treatment adherence 
making it difficult to conceptualize the scope of the problem and to target intervention strategies 
to promote adherence (Emilsson, Gustafsson, Ohnstrom, & Marteinsdott, 2017; Osterberg & 
Blaschke, 2005).  Though it is clear that rates of medication adherence decline significantly over 
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time, partially due to these limitations, there is currently no clear estimation of adherence rates in 
the emerging adult and adult populations with ADHD.  The identified factors (e.g., social stigma, 
treatment ineffectiveness) in the adult adherence literature, however, are consistent with a 
developmental model for treatment adherence and may explain the trends in adherence rates over 
time (Ahmed & Aslani, 2013; Gajria et al., 2014).  Based on the limited research on children and 
adults with ADHD, it is hypothesized that a variety of factors contribute to low rates of treatment 
adherence (Corkum et al., 2013).  Contributing factors that have been identified in the literature 
are comprised of some unchangeable variables (i.e., individual demographic factors), but also 
others that are malleable (e.g., attitudes towards treatment) and can be targeted by clinicians to 
improve adherence.  The extent to which each of these factors individually contributes to 
treatment adherence is currently unstudied; however, it is clear that a combination of variables 
may influence treatment adherence. 
Individual characteristics. 
Demographic risk factors.  Certain patient demographic factors (i.e., family history of 
ADHD, ethnicity, gender) were implicated in contributing to poor treatment adherence (Charach 
& Fernandez, 2013).  These factors are largely inalterable, but may indirectly contribute to 
treatment outcomes based on adherence.  For example, family history of ADHD is one factor 
related to decreased adherence, presumably due to the caregiver’s lack of organization and poor 
management skills associated with ADHD (Gau et al., 2008). Racial or ethnic minority status 
(i.e., Hispanic, African-American) has also been cited as a factor related to treatment adherence 
(Berger-Jenkins et al., 2012).  Lower rates of treatment adherence for minority populations have 
been associated with cultural beliefs and skepticism about mental illness and treatment, and less 
knowledge about ADHD and treatment (Arcia, Fernandez, & Jaquez, 2004; Bussing, Gary, 
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Mills, & Garvan, 2007).  Additionally, past studies have documented gender as relating to 
treatment adherence, with females exhibiting higher rates of adherence than males (Atzori et al., 
2009; Chacko et al., 2010; Miller, Lalonde, & McGrail, 2004).   
Symptomotology.  
ADHD symptom severity. Symptoms of ADHD and other psychiatric disorders have also 
been associated with treatment adherence (Ahmed & Aslani, 2013; Atzori et al., 2009).  
Individuals with higher levels of baseline ADHD symptoms tend to have lower rates of treatment 
adherence (Charach & Gajaria, 2008; Charach, Ickowicz, & Abel, 2004).  Considerations that 
may contribute to this phenomenon include increased adverse side-effects associated with higher 
doses of medication (Atzori et al., 2009) as well as increased ADHD symptom severity possibly 
impeding self-regulatory responsibilities necessary for adherence. 
 Comorbid symptoms. There have been mixed findings on the relationship of comorbid 
diagnoses to treatment adherence with some studies indicating worsened adherence with the 
presence of comorbidities (Charach et al., 2004; Corkum et al., 2015; Thiruchevlam et al., 2001), 
and others indicating improved adherence (Atzori et al., 2009; Palli, Kamble, Chen, & Aparasu, 
2012).  Contributing factors of comorbidities to adherence may be related to the use of multiple 
medications to manage symptoms or higher symptom severity that would lead to an increased 
perceived benefit or difficultly managing treatment.  For these reasons, differences in findings 
may be related to comorbid diagnosis type (e.g., oppositional defiant disorder, anxiety disorder, 
conduct disorder, learning disability) and prior medication habits (Corkum et al., 2015).  When 
individuals are generally noncompliant with medication regimens, as often is the case for 
individuals with severe ADHD, it is probable that the higher symptom severity of individuals 
with comorbid ADHD is associated with lower levels of treatment adherence.  However, the 
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presence of multiple comorbidities may increase the need for and benefits of medication, 
potentially contributing to higher rates of treatment adherence.  Because individuals with ADHD 
are at increased risk for displaying comorbid disorders, this is a particularly importance facet of 
treatment adherence to examine for this population (Anastopoulos et al., 2106). 
Medication tolerability. Corkum and colleagues (2013) identified a variety of medication-
specific factors related to adherence.  A main consideration of medication usage related to 
adherence is tolerability (Gajaria et al., 2014).  Tolerability of medication (i.e., acceptableness of 
use) can be related to multiple factors including ease of use, adverse side-effects, fear around 
long-term effects of medication, and stigma about ADHD treatment (Gau et al., 2008; Johnston, 
Hommersen, & Seipp, 2008; Wong et al., 2009).  In general, children and adults exhibit greater 
adherence to long-acting medications than short-acting medications (Christensen et al., 2010; 
Gau et al., 2008; Wong et al., 2009).  This difference is attributed to the convenience of taking 
medication once a day rather than multiple times.  The reduced administration efforts associated 
with long-acting medications minimize the chance of forgetfulness and maximize the ease of 
treatment.   
The type of medication and dosing is also related to treatment adherence.  Specifically, 
stimulant medications are associated with better treatment adherence than non-stimulant 
medications (Christensen, Sasane, Hodgkins, Harley, & Tetali, 2010) and both children and 
adults demonstrate higher rates of adherence to amphetamines than methylphenidates 
(Christensen et al., 2010; Gajria et al., 2014).  These differences are potentially attributable to 
augmentation and medication switching rates, which may compromise the stability of treatment, 
thereby negatively influencing adherence rates (Christensen et al., 2010).  For example, when 
medications are constantly changed and adjusted, it may become more difficult for individuals to 
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follow their treatment regimen with fidelity.  Individuals receiving higher doses of medication 
also tend to have lower adherence (Ahmed & Aslani, 2013).  This difference can be attributed to 
presumably more severe symptomatology warranting the need for higher dosing of medication 
(Atzori et al., 2009) or to the increased adverse side-effects resultant of higher medication 
dosages (Wong et al., 2009). 
For adolescents in particular, increased adverse side-effects have been identified as a 
common contributor to treatment nonadherence (Bussing et al., 2012; Charach & Fernandez, 
2013; Kendall, Hatton, Beckett, & Leo, 2003).  Adverse side-effects common to psychostimulant 
medications (e.g., appetite reduction, emotional labiality, difficulty sleeping) may lead to 
decreased tolerability, and therefore, decreased medication usage (Charach & Fernandez, 2013; 
Fleming & McMahon, 2012).  Despite the benefits of these treatments, certain individuals may 
experience limited tolerability for medication that may preclude optimal usage.  The tolerability 
of these treatments may be highly influential in individuals’ attitudes towards treatment.  Various 
characteristics of prescribed treatment regiments can lead to more or less intense costs and 
benefits to treatment, an important component of treatment use (Horne & Weinman, 1999). 
 Attitude towards treatment. 
 Because the aforementioned individual characteristics are largely unchangeable, it is 
necessary to target malleable factors related to treatment adherence.  Currently, the relative 
influence of individual characteristics to attitudes towards treatment and/or treatment adherence 
for the college population is unknown.  Attitudes towards treatment present a possible point of 
intervention to promote treatment adherence.  However, it is necessary to examine the extent to 
which attitudes towards treatment influence the relationship between individual characteristics 
and treatment adherence in order to empirically evaluate whether attitudes constitute a fruitful 
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point of intervention for promoting adherence. 
Adherence is related to the extent that an individual’s perceived benefits of treatment 
outweigh the treatment costs (Emilsson et al., 2017; Horne & Weinman, 1999).  This relationship 
likely explains the reasoning that tolerability of treatment has been cited as an important factor 
influencing treatment adherence (Gajria et al., 2014).  The positive differential belief in the 
necessity of the medication versus the concerns of medication and levels of adverse side-effects 
is strongly associated with treatment adherence (Emilsson et al., 2017).  Although some 
components related to tolerability are more difficult to change (e.g., side-effects, ease of 
administration), other components that tolerability of medication may predict (e.g., attitudes) can 
be targeted to increase the perceived benefits of treatment. 
Currently, there is no best practice method for promoting treatment adherence; however, 
recommendations for promoting adherence typically focus on strategies to increase the perceived 
treatment benefits relative to the costs.  The cognitive-behavioral model of psychology 
emphasizes altering cognitions in order to change behavior (Dobson, 2010).  Based on the 
application of this theoretical orientation, in order to promote behavior change (i.e., treatment 
adherence), it is necessary to alter cognitions (i.e., thoughts about impairment, knowledge) about 
treatment for ADHD.  Based on this model, strategies that emphasize the promotion of perceived 
benefits of treatment may be an effective way to influence behavioral change in the form of 
treatment adherence.  For this reason, it is necessary to examine attitudes towards treatment (i.e., 
malleable factors such as knowledge, perceived impairment from ADHD, and satisfaction with 
treatment) in order to inform possible interventions to promote treatment adherence. 
 Knowledge.  Health literacy is an important aspect of treatment; individuals should be 
well informed about the need for and benefits of treatment for ADHD (Charach & Fernandez, 
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2013).  Despite compelling research, there are still many misconceptions and heightened stigma 
about individuals with ADHD (Moldavsky & Sayal, 2013).  Some of the main areas that 
reinforce stigma concern the etiology and treatment of ADHD (e.g., inadequate parenting skills), 
due to inaccuracies of knowledge about these domains.  This stigma, resulting from inaccurate 
knowledge, may impact help-seeking behaviors, and therefore interventions should target 
reversing these misconceptions by improving the knowledge base surrounding ADHD and 
treatment.  Currently, there is no clear direction identified in the research for the knowledge base 
that is most likely to improve treatment adherence, but by providing individuals with a 
comprehensive, accurate, and realistic expectation of the benefits and risks associated with 
treatment and non-adherence, individuals will be able to make better informed, evidence-based 
decisions and adjust their attitudes related to treatment (Charach & Fernandez, 2013). 
Psychoeducation is commonly targeted as a behavioral treatment strategy to promote 
adherence in adult populations with other mental illnesses (Kemp, Hayward, Applewhaite, 
Everitt, & David, 1996; Montoya, Colom, & Ferrin, 2011; Unutzer, et al., 2001).  Although 
many interventions to promote adherence to ADHD medication suggest an educational 
component, there is limited research to confirm that this is an effective strategy (Montoya et al., 
2011).  Corkum, Rimer, and Schachar (1999) demonstrated that knowledge about ADHD may 
increase willingness to initiate pharmacological treatment, but did not document significant 
changes to treatment adherence.  Similarly to adherence, treatment willingness is influenced by 
perceptions and attitudes (e.g., feeling knowledgeable about treatment; Bussing et al., 2012).  
Theoretically, knowledge about the benefits of treatment should help to alter attitudes and 
promote treatment adherence.  However, due to methodological flaws in the scant examination 
of this phenomenon, the current research on the influence of knowledge on treatment adherence 
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is inconclusive (Emilsson et al., 2017; Osterberg & Blaschke, 2005).  Despite the ambiguous 
nature of available research, knowledge and psychoeducation is still targeted as a common 
strategy to promote adherence.  To support the efficacy of this type of intervention, it is critical 
to examine the influence of knowledge about ADHD and its treatment on treatment adherence. 
 Perceived Impairment from ADHD.  Thoughts about impairment from and treatment for 
ADHD can be critical factors in treatment use and adherence (Bussing et al., 2012; Emilsson et 
al., 2017).  As discussed previously, ADHD can cause significant short and long-term 
impairments for individuals that can influence multiple aspects of their lives (Arnold, Hodgkins, 
Caci, Kahle, & Young, 2015; Fleming & McMahon, 2012; Weyandt et al., 2013).   Although 
there is strong evidence to support the efficacy of ADHD medication in improving outcomes and 
symptom expression, there are also significant adverse effects associated with treatment (e.g., 
side effects, stigma; Fleming & McMahon, 2012; Moldavsky & Saval, 2013).  If, however, 
perceived impairment from ADHD does not exceed the adverse effects from alternatives (i.e., no 
treatment, treatment) individuals will have little reason to sustain treatment efforts. 
 Willingness to engage in treatment, a necessary prerequisite to treatment adherence, is 
related to an individual’s expectations of treatment effectiveness (Bussing et al., 2012).  
Individuals who expect positive outcomes from treatment for ADHD will be more likely to 
engage in treatment efforts than those who do not. Perceptions of impairment from ADHD can 
also be highly influential in an individual’s decision to initiate and adhere to treatment.  Emilsson 
and colleagues (2017) found that, for adolescents with ADHD, adherence is related to the degree 
to which an individual’s belief in the necessity of treatment overrides the individual’s concern 
about treatment risks.  A positive differential of belief in the necessity of medication can have 
profound impacts on the treatment adherence habits of this population.  For this reason, it is 
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important to understand the ways in which an individual’s perceptions of their impairment relate 
to treatment adherence. Although it might not be feasible to eliminate the adverse effects of 
medication, it is possible to alter individuals’ understanding of their impairment from and need 
for treatment for ADHD. 
Satisfaction.  Once treatment is initiated, the perceived effectiveness and utility (i.e., 
satisfaction) of treatment is highly correlated with willingness to adhere to treatment (Charach & 
Fernandez, 2013; Wong et al., 2009).  Beliefs about the need for, safety of, and effectiveness of 
medications are highly influential factors in promoting adherence (Bussing et al., 2012; DosReis 
et al., 2009; Gearing et al., 2011).  Individuals are unlikely to adhere to treatments that are too 
burdensome or are perceived as unsafe, inappropriate, or unnecessary (Charach & Fernandez, 
2013).  Additionally, treatment efficacy is an important factor related to adherence, as 
individuals are less likely to adhere to treatment recommendations when they do not perceive 
any symptomatic improvement (Wong et al., 2009). 
Individuals who are satisfied with improvements from their treatments are more likely to 
exhibit treatment adherence (Chacko et al., 2010).  For example, Hebert, Polotskaia, Joober, and 
Grizenko (2013) found that children with parents who perceived significant psychosocial 
benefits of treatment for ADHD had greater adherence with their treatments than those whose 
parents did not.  Both attitudes towards treatment effectiveness (Hebert et al., 2013) and actual 
treatment effectiveness (Ahmed & Aslani, 2013; Wong et al., 2009) are critical factors in 
treatment adherence.  Therefore, it is necessary to understand individuals’ satisfaction with their 
treatment in order to promote treatment adherence. 
Developmental Model for Treatment Adherence 
 ADHD is a chronic condition that persists throughout adulthood, and therefore 
  
20 
individuals commonly must adhere to treatment regimens over long periods of time (Ahmed & 
Aslani, 2013; Chacko et al., 2010).  Patterns of treatment adherence, however, shift across the 
lifespan.  Age has been identified as a particularly important contributor to treatment adherence 
with rates declining from childhood to adulthood (Ahmed & Aslani, 2013; Corkum et al., 2013).  
To optimize success, the AAP recommends considering treatment for ADHD within a 
developmental context in order to reflect differences across age groups (Sibley, Kuriyan, Evans, 
Waxmonsky, & Smith, 2014). 
The current literature on treatment adherence for ADHD is limited and focuses mainly on 
childhood populations.  However, due to differences in barriers to treatment across the lifespan, 
the child research base may not be completely applicable to older populations (e.g., adolescents, 
young adults, adults; Sibley et al., 2014), and best practice treatment might vary to most 
effectively accommodate individuals in different developmental stages.  Specific barriers to 
treatment adherence for each age group should be considered in order to understand where to 
target intervention efforts to promote treatment adherence for ADHD. 
Across all age groups of individuals with ADHD, treatment adherence rates are low 
(Hong et al., 2013).  The reasons for these low rates, however, differ across populations as 
adolescents and adults face different obstacles to treatment adherence for ADHD than children 
(Ahmed & Aslani, 2013).  In the childhood population, for example, children often have limited 
clinical power over their treatment, and have to defer to the decisions of their parents and 
healthcare providers (Matsui, 2007).  Presumably due to higher levels of parent involvement 
(Atzori et al., 2009), typically, younger children are more likely to comply with 
psychopharmacological treatments (Atzori et al., 2009; Barner, Khoza, & Oladapo, 2011; 
Berger-Jenkins, McKay, Newcorn, Bannon, & Laraque, 2012; Gau et al., 2008; Miller et al., 
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2004; Thiruchelvam et al., 2001) with adults demonstrating the lowest medication adherence 
rates (Ahmed & Aslani, 2013). 
As children get older, they gain independence, autonomy, and control over their medical 
treatment, putting the responsibility of medication adherence on the individual rather than their 
caregivers (Chacko et al., 2010).  This greater independence in combination with symptomatic 
changes, a common occurrence in the progression of ADHD, can lead to decreased medication 
usage (Atzori et al., 2009).  Although this is a critical stage for treating ADHD in terms of future 
health outcomes (e.g., driving, risk taking, education; Fleming & McMahon, 2012; Sibley et al., 
2014), adolescents in the process of parental detachment and increasing responsibility over their 
health care may be especially prone to nonadherence (Brinkman et al., 2012).  Despite persistent 
symptomatic impairment (Sibley et al., 2014), adolescents tend to prefer self-reliance over 
formal treatment for mental health help-seeking and may exhibit acts of rebellion (e.g., 
terminating treatment) in order to establish their independence (Gulliver, Griffiths, & 
Christensen, 2010).  Adolescents with ADHD tend to underestimate or deny impairment (Fischer 
et al., 1993).  Further, stigma associated with ADHD treatment (Moldavsky & Sayal, 2013) and 
lack of motivation to take medication (Kent et al., 2011) are particularly pertinent treatment 
barriers for individuals at this developmental stage.  For a variety of reasons, adolescents are less 
willing to use medication than adults (Bussing et al., 2012; Charach & Fernandez, 2013) and 
may resist treatments for their ADHD (Barkley et al., 2001).  Unlike in childhood, however, 
where caregivers are largely responsible for treatment decisions, adolescents typically make 
decisions about treatment termination (McCarthy, 2014).  By the end of high school, up to 90% 
of individuals with ADHD refuse and cease pharmacological treatment for ADHD (Biswas, 
Gnagy, Molina, & Pelham, 2009).  These changes in patterns of adherence support the 
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importance of alterable factors (e.g., attitudes towards treatment) that may best predict treatment 
adherence across different periods of the lifespan.  Additionally, the relationship of the 
unchangeable factors to treatment adherence may differ over the lifespan (e.g., family history of 
ADHD may impact adherence more when the parent is in charge of child’s treatment), making 
attitudes an even more pertinent influence to treatment adherence during emerging adulthood. 
The research base on college students with ADHD is even more limited (DuPaul, 
Weyandt, O’Dell, & Varejao 2009; Fleming & McMahon; Green & Rabiner, 2012).  In general, 
emerging adulthood has been identified as a critical period for establishing patterns of treatment 
adherence (Pai & Ostendorf, 2011).  Across a variety of chronic illness conditions, treatment 
adherence rates tend to decline significantly as children transition from pediatric to adult-based 
medical care (i.e., emerging adulthood; Annunziato et al., 2007; Kipps et al., 2002; Watson, 
2000).  In the college setting, parental involvement becomes even more limited than in 
adolescence and individuals gain greater control over their treatment decisions (Fleming & 
McMahon, 2012).  For individuals with ADHD in particular, the loss of structure and parental 
support in addition to increased demands on executive functioning may create significant and 
unique barriers to treatment.  In an analysis of adherence patterns to psychopharmacological 
treatment among college students with ADHD, college students adhered only to about half of 
their prescribed doses (Gray et al., 2018).  Gray and colleagues identified the transition to college 
as a highly risky time for poor self-management of ADHD, citing the lowest adherence rates 
during the beginning of college, with rates of adherence during the college years improving over 
time.  As with adolescents, it is clear that individuals with ADHD in the college setting continue 
to face significant impairment from the disorder.  College students may experience specific 
challenges related to tolerability and attitudes towards treatment.  The perceived cost and lack of 
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satisfaction with treatment in this population may override the motivation for treatment 
adherence (Meaux, Hester, Smith, & Shoptaw, 2006; Rabiner, Anastopoulos, Costello, Hoye, & 
Swartwelder, 2008).  The idiosyncratic characteristics of college students with ADHD 
necessitate individualized intervention strategies that specifically target treatment barriers 
relevant to this population.  Despite this understanding, there is a dearth of research that 
specifically assesses factors related to treatment adherence in the emerging adult population with 
ADHD or with chronic illnesses in general (Pai & Ostendorf, 2011).  It is critical to understand 
factors that may influence treatment adherence for college students with ADHD in order to target 
intervention efforts that maximize short and long-term outcomes. 
Proposed Study 
 Treatment adherence for chronic health conditions is an important mental and public 
health issue (Truer et al., 2016).  For emerging adults with ADHD, low rates of treatment 
adherence preclude individuals from the long-term health benefits of evidence-based treatments 
for ADHD, and instead leave them vulnerable to the negative outcomes associated with the 
disorder.  Because, however, patterns of adherence change across development, it is likely that 
certain aspects related to treatment adherence are alterable and may serves as a point of 
intervention.  Despite serious health concerns, we know little about factors impacting treatment 
adherence in the adult ADHD population.  Further, the scant research that does exist mainly 
focuses on the pediatric population and, due to developmental differences, may not be applicable 
to adults with ADHD. 
The present study aims to address limitations to the extant literature by examining factors 
related to treatment adherence to pharmacological treatments in college students with ADHD.  
Due to methodological limitations in the ability to specifically quantify and measure 
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psychosocial treatments as well as the limited information on factors related to adherence for 
these types of treatments, to increase the validity of study results, the scope of this study is 
limited to examining adherence to psychopharmacological treatments rather than psychosocial 
treatments.  Similarly consistent with past adherence studies and particularly because this was an 
observational rather than an interventional study, concentrating on more standardized 
psychopharmacological treatments will provide a more accurate and informative understanding 
of the ways that various identified factors relate to treatment adherence in this population. 
 In the childhood literature, a variety of factors related to treatment adherence have been 
identified (Charach & Fernandez, 2013).  Although the strengths of these relationships are 
unknown, individual characteristics (i.e., gender, ethnicity, family history of ADHD, ADHD 
symptom severity, and comorbidities) as well as attitudes have been previously established as 
relating to treatment adherence (Arcia, Fernandez, & Jaquez, 2004; Atzori et al., 2009; Bussing, 
Gary, Mills, & Garvan, 2007; Chacko et al., 2010; Miller, Lalonde, & McGrail, 2004; Gau et al., 
2008).  Medication tolerability has also been consistently cited as one of the most common 
reasons for decreased rates of treatment adherence in this population (Gau et al., 2008; Johnston, 
Hommersen, & Seipp, 2008; Wong et al., 2009).  Although the relationship between medication 
tolerability and attitudes has not been empirically explored, presumably the tolerability of 
medications is greatly influential in individual appraisal of the costs and benefits of treatment use 
(i.e., attitudes towards treatment).  For this reason, it is expected that medication tolerability and 
attitudes towards treatment are also highly related constructs (e.g., more tolerable medication 
may lead to greater perceived benefit; more negative attitudes towards treatment may lead to 
lower tolerability of medication side-effects).  Based on this theoretical understanding of the 
relationship between these two constructs, it is likely that the relationship between medication 
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tolerability and treatment adherence is better explained by individual’s attitudes towards 
treatment than the tolerability of the medication itself. 
 To address the gap between what is known and what is needed in relation to treatment 
adherence, the first purpose of this study was to examine the specific individual relationships of a 
variety of identified factors (i.e., risk factors, ADHD symptom severity, comorbidities, 
medication tolerability, and attitudes towards medication) to treatment adherence in college 
students with ADHD.  Additionally, as previously explained, existing literature cites medication 
tolerability as an important factor in treatment adherence (Gau et al., 2008; Johnston, 
Hommersen, & Seipp, 2008; Wong et al., 2009).  Unchangeable tolerability factors (e.g., 
medication type, side-effects), however, may have a strong influence on individuals’ attitudes 
towards treatment, which in the emerging adult population in particular, has been hypothesized 
to have a strong influence on treatment adherence.  Based on this theoretical relationship and 
because individual characteristics are largely unchangeable, while factors related to attitudes 
towards ADHD may be alterable through intervention efforts, the second purpose of this study 
was to examine if the relationship between the latent construct of medication tolerability is 
mediated by the latent construct of attitudes towards treatment when controlling for other 
individual characteristics (i.e., demographic risk factors [family history of ADHD, ethnicity, 
gender], ADHD symptom severity, and number of comorbid diagnoses).  This study aimed to 
answer the following research questions; 
1. What are the unique relationships of demographic risk factors, ADHD symptom severity, 
comorbidities, medication tolerability, and attitudes towards treatment with treatment 
adherence in college students with ADHD? 
2. Does the latent construct of attitudes towards treatment mediate the relationship between 
  
26 
the latent construct of medication tolerability and treatment adherence when controlling 
for demographic risk factors, ADHD symptom severity, and comorbidities?  More 
specifically, (A) is there a significant relationship between medication tolerability and 
treatment adherence?  (B) Does attitudes towards treatment mediate that relationship? 
(i.e., [a] is there a significant relationship between medication tolerability and attitudes 
towards treatment?, [b] is there a significant relationship between attitudes towards 
medication and treatment adherence?, and [c] is the relationship between medication 
tolerability and treatment adherence significantly reduced or eliminated when controlling 
for attitudes towards treatment?) 
 It was hypothesized that all identified variables (i.e., demographic risk factors, ADHD 
symptom severity, comorbidities, medication tolerability, and attitude towards treatment) would 
be significantly related to treatment adherence.  More specifically, given the evidence to support 
the importance of attitudes towards treatment for the adolescent and emerging adult populations, 
attitudes would have the strongest correlation with treatment adherence.  Additionally, it was 
hypothesized that attitude towards treatment would mediate the relationship between medication 
tolerability and treatment adherence (For primary proposed model, see Figure 1). 
 In order to utilize a model that would provide the most accurate representation of the data 
and to prevent confirmation bias, an alternative model was also proposed (see Figure 2).  In the 
secondary model, demographic risk factors were further separated into individual predictors (i.e., 
gender, ethnicity, and family history of ADHD) to assess if those risk factors are more accurately 
analyzed individually, rather than as a total score.  Because there is no information from the 
literature on the extent to which each variable will be related to treatment adherence (e.g., 
whether gender is more influential than ethnicity), to find the best representation of the data, 
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demographic risk factors were analyzed both individually and together.  All other aspects of the 
model are identical to the primary proposed model. 
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CHAPTER 2 
Method 
Participant Recruitment 
 Data for this study were taken from a larger, longitudinal study examining the long-term 
outcomes of college students with ADHD (Anastopoulos et al., 2016).  The purpose of the 
original study was to collect data on educational outcomes; cognitive, social, and vocational 
functioning; and use of treatment services to better understand the long-term impact of ADHD 
on college students.  At the time of the proposed study, the original study was ongoing.  
Participants in the original study were college students recruited from 12 colleges and 
universities in North Carolina, Pennsylvania, and Rhode Island.  Two cohorts of first-year 
college students were recruited over a span of two consecutive years.  Two groups of students, 
individuals with ADHD (n=204) and comparisons without ADHD (n=215), were recruited for 
the original study.  Students volunteered in response to various campus recruitment efforts (e.g., 
campus fairs, Facebook, office of disability referrals, fliers).  In exchange for their participation, 
individuals received up to $100 for each year of participation in the study as well as a report to 
provide them with information about their functioning.  All students were screened prior to their 
inclusion in the study to determine their eligibility for participation.  Approval for the study was 
obtained from the Institutional Review Boards (IRB) from each university, and all participants 
consented to participation in the study. 
Screening Procedures and Group Designation 
Group designation was based on multiple diagnostic measures.  Participants completed 
two versions (childhood and past 6-months) of an ADHD Rating Scale and a semi-structured 
ADHD interview to determine their eligibility for the study.  The ADHD Rating Scale was 
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developed for this study and was based on the Diagnostic and Statistical Manual of Mental 
Disorders 4th edition-text revision criteria for adult ADHD (DSM-IV-TR; American Psychiatric 
Association, 2000).  Parents of participants also completed the ADHD Rating Scale-IV: Parent 
Version (DuPaul et al., 1998).  Criteria for inclusion in the ADHD group required that either 
students or their parents indicated that students exhibited four or more symptoms of 
hyperactivity/impulsivity or inattention on the ADHD Rating Scales both in childhood (prior to 
the age of 12) and in the past six months.  Additionally, on a semi-structured ADHD interview, 
individuals needed to indicate that five or more symptoms of hyperactivity/impulsivity or 
inattention were present prior to the age of 12 to be included in the ADHD group.  The ADHD 
semi-structured interview was also developed for this study and was based on DSM-5 adult 
ADHD criteria (American Psychological Association, 2013).  The interview addressed symptom 
presentation as well as impairment. 
Finally, each participant was screened using the Structured Clinical Interview for DSM 
Disorders (SCID-I; First, Gibbon, Spitzer, & Williams, 2002) and evaluated by a panel of four 
licensed psychologists (the principal investigators of the original study and a clinical 
psychologist consultant) to ensure that hyperactive/impulsive and/or inattentive symptoms were 
due to ADHD rather than another disorder or condition.  The panel of psychologists used a 
combination of information to determine comorbid diagnoses.  Panel members independently 
reviewed specific diagnosis and interview information generated from the SCID-I (First et al., 
2002) as well as scores from the Beck Anxiety Inventory (Beck & Steer, 1993), the Beck 
Depression Inventory-Second Edition (Beck, Steer, & Brown, 1996), and the Externalizing 
Behavior Rating Scale, and assigned diagnoses based on those data.  The panel discussed any 
diagnostic disagreements until a consensus was achieved. 
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Individuals in the comparison group needed to report fewer than four symptoms of 
hyperactivity/impulsivity and inattention on the ADHD Rating Scales as well as fewer than four 
symptoms on the semi-structured ADHD interview.  Those who did not meet all criteria for 
either the ADHD or comparison group were excluded from the study.  For the proposed study, 
only individuals with a diagnosis of ADHD, with complete data, who reported past use of 
medication for behavior management purposes were included in the analysis.     
Participant Description 
For the purposes of the current study, year one data from students who met research 
criteria for ADHD and indicated that they had used ADHD-related medication at any point since 
the beginning of the Fall semester of their first year of college were examined (i.e., answered 
“yes” to “at any time during the fall semester, did you take medication for ADHD-related 
difficulties”; [n=99 out of 204 total participants with ADHD]).  An additional five participants 
were excluded from analysis due to incomplete data (see Figure 1).  Participants for the current 
study were college first-year students with ADHD who endorsed the use of ADHD medication 
within the past year (N = 94, 43 = men, 51 = women) ranging from the ages of 18-22 (M = 18.22; 
SD = 0.55).  The sample was 81.9% Caucasian/non-Hispanic and 18.1% non-Caucasian or 
Hispanic.  Year 1 data from cohorts 1 and 2 were collected for this study over two consecutive 
years (51 = cohort one, 43 = cohort two).  An independent samples t-test between groups on age 
and a series of chi-square analyses on relevant variables (i.e., gender, race, ethnicity) confirmed 
that there were no statistically significant differences in the demographic characteristics of the 
two cohorts.  Additionally, a series of comparative tests on individual characteristics (i.e., 
independent samples t-tests on a number of comorbidities, ADHD severity, and total risk factors; 
chi-squared analyses on gender, ethnicity, and family history of ADHD) revealed that aside from 
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number of comorbid diagnoses, there were no significant differences between the demographic 
factors of individuals with ADHD who were or were not included in the present analysis.  
Individuals with ADHD who were excluded from the analysis, had higher numbers of comorbid 
diagnoses (M=.94, SD=.98) then those who were included in the analysis (M=.66, SD=.71); 
t(227)=2.39, p=.018.  
Although it is typically recommended that a minimum of 200 participants are included 
for analysis in a structural equation model, Schumacker and Lomax (2010) indicate that, in 
certain cases, it is possible to conduct a structural equation model with 100 participants (i.e., 
simple model with a plan for replication).  Based on this recommendation, although the sample 
for this analysis was smaller than the recommended sample size and did not meet all of the 
recommended criteria, because college students with ADHD who are taking medication are a 
difficult sample to access, it was decided that the sample size for the present study was 
acceptable to perform the analysis. 
Materials 
Screening measures. 
ADHD Rating Scale, Self-Report Version. 
 Childhood Version.  The ADHD Rating Scale-Childhood Version was created for use in 
the larger TRAC study.  The 18 items on the rating scale are based on the DSM-IV-TR criteria 
for ADHD and tap symptoms of inattention and hyperactivity-impulsivity (American Psychiatric 
Association, 2000).  Participants were instructed to rate their behavior as a child prior to 12 years 
of age on a 4-point Likert scale (0 = never or rarely, 3 = very often) with higher scores indicative 
of more severe ADHD symptomatology.  Total inattention and hyperactivity-impulsivity 
subscores are calculated by summing the number of items (n=9) with scores of 2 or higher.  
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Before completing the measure, participants were asked if they were receiving medication for 
behavior management purposes before they were 12-years-old.  If they answered yes, they 
completed the questions thinking about their behavior when they were not taking this medication 
(i.e., never on medication).  If they answered no, they completed the questions thinking about 
their typical behavior (i.e., behavior when not taking medication).  To qualify for the ADHD 
group based on research criteria, participants needed to rate themselves with a score of two or 
higher on four or more symptoms of either hyperactivity/impulsivity or inattention. 
Past 6 Months Version.  The ADHD Rating Scale-Past 6 Months is identical to the 
ADHD Rating Scale-Childhood Version except participants completed it based on their behavior 
in the past 6 months rather than before the age of 12.  Before completing the measure, 
participants were asked if they had been receiving medication for behavior management 
purposes during the past 6 months.  If participants indicated that they had not been receiving 
medication, they responded to scale items accordingly.  If participants indicated that they had 
been receiving medication, they responded to each item in two ways: when they were taking 
medication and when they were not taking medication during this time period. 
In the full sample (N=443), both the Childhood and Past 6 Months versions of the ADHD 
Rating Scale demonstrated adequate levels of internal consistency (=.74-.94; Anastopoulos et 
al., 2016).  Additionally, these measures demonstrated adequate levels of concurrent validity 
with statistically significant correlations between corresponding subscales on the Conners’ Adult 
ADHD Rating Scale- Self Report: Long Version (CAARS; Conners, Erhardt, & Sparrow, 1999) 
ranging from .27 to .92 (Anastopoulos et al., 2016). 
 ADHD Rating Scale-IV: Parent Version. The ADHD Rating Scale-IV: Parent Version is 
an existing measure that was sent to parents so that diagnostic information about participants 
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could be collected from multiple sources (DuPaul et al., 1998).  The scale has the same items as 
the ADHD Rating Scale-Childhood Version and the Past 6 Months Version; however, the 
wording on each item reflects that the questions are asking about the individual’s child, rather 
than the individual completing the questionnaire.  Parents were instructed to respond to each 
item thinking about their child’s behavior when children were not taking medication.  Parents 
gave two behavior ratings for each item.  The first rating addressed their child’s behavior from 
the ages of 5-12 and the second rating addressed their child’s behavior in the past 6-months. The 
ADHD Rating Scale-IV: Parent Version has adequate internal consistency ( = .92) and 
discriminant validity (DuPaul, Power, Anastopoulos, & Reid, 1998). 
 Semi-Structured ADHD Interview.  The Semi-Structured ADHD Interview was created 
for the larger TRAC study to address symptom presentation and impairment.  The interview is 
based on DSM-5 adult ADHD criteria and includes nine questions about symptoms of inattention 
and nine questions about symptoms of hyperactivity/impulsivity (American Psychological 
Association, 2013).  Additionally, if participants endorsed the presence an ADHD symptom 
either taking or not taking medication, they were asked if the presentation of the symptom had 
caused problems for them in a variety of settings.  If participants indicated four or more 
symptoms, they were also asked about age of symptom onset and concerns about symptoms. 
In the full sample (N=456), the internal consistency for symptom responses on the semi-
structured interview was 0.90 for attention and 0.85 for hyperactivity-impulsivity. Correlations 
between responses on the interview and CAARS scores were 0.78 for inattention and 0.84 for 
hyperactivity-impulsivity (Anastopoulos et al., 2016). 
Individual characteristics. 
Demographics.  Participants completed a demographic questionnaire to indicate their 
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age, gender, ethnicity, race, and marital status. 
Family history of ADHD. During an orally administered background interview, 
participants were asked to report if anyone in their family (i.e., yourself, siblings, mother, father, 
extended relatives) had a history of ADHD.  Participants also indicated if the history of ADHD 
was suspected or diagnosed.  For the purposes of this study, individuals were considered to have 
a family history of ADHD if they reported that any member of their family (i.e., immediate or 
extended) had diagnosed (i.e., not suspected) ADHD. 
The variable representing demographic risk factors was calculated by summing the total 
number of risk factors each participant endorsed ranging from 0-3 (i.e., male, non-White, family 
history of ADHD) with higher values indicating greater risk. 
ADHD Symptoms. ADHD symptoms were calculated as the total number of symptoms 
of hyperactivity-impulsivity and inattention, when not taking medication that participants 
reported on the ADHD Rating Scale-Past 6 Months version (measure described previously). 
Comorbid Symptomotology. Decisions on comorbid diagnoses were determined through 
the expert panel review (described previously) based on information collected through the 
Structured Clinical Interview for DSM Disorders (SCID-I; First et al., 2002), Beck Anxiety 
Inventory (BAI; Beck & Steer, 1993), Beck Depression Inventory-Second Edition (BDI-II; Beck, 
Steer, & Brown, 1996), and Externalizing Behavior Rating Scale. 
Structured Clinical Interview for DSM Disorders (SCID-I).  The SCID-I is a computer-
based semi-structured interview based on the DSM-IV-TR criteria (American Psychiatric 
Association, 2000) that is used to assess clinically significant presentations of psychiatric 
disorders (First et al., 2002).  For the purposes of this study, only the modules for mood episodes, 
mood disorders, and anxiety disorders were used.  Trained graduate assistants in Ph.D. or 
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Masters level clinical and school psychology programs conducted the SCID-I interviews.  During 
the interview, individuals were asked specifically about symptoms of mood and anxiety 
disorders, but were given the opportunity to respond and elaborate in an unstructured format.  
Interviewers either endorsed or did not endorse the structured question presented on the SCID-I.  
The SCID-I has adequate inter-rater reliability with kappa levels between .70 and 1.00 (First et 
al., 2002). 
Beck Anxiety Inventory (BAI).  The BAI is a self-report measure of anxiety  
symptom severity in adults (Beck & Steer, 1993). The scale includes 21 items that measure 
symptom severity over the past week. Each item is rated on a 4-point Likert scale (0 = not at all, 
3 = severely) with higher scores indicating greater severity of anxiety symptoms. Total scores are 
calculated by creating a sum of all of the items; individuals who score higher on the BAI are 
more likely to be experiencing more severe symptoms of an anxiety disorder. The BAI has 
adequate levels of internal consistency (α = .92) and concurrent validity (Beck, Epstein, Brown, 
& Steer, 1988).   
Beck Depression Inventory- Second Edition (BDI-II). The BDI-II measures depression 
symptom severity among adults, where adults self-report symptom severity over the past 2 weeks 
(Beck, Steer, & Brown, 1996). The scale includes 21 items, and each item provides response 
options rated on a 4-point scale (0 = not at all, 3 = severely). Higher ratings on each question 
indicate greater severity of depression symptoms. The BDI has been shown to include high 
levels of reliability and validity in adults as well as in college students (Sprinkle et al., 2002).  
 Externalizing Behavior Rating Scale. The Externalizing Behavior Rating Scale is a self-
report measure of externalizing behavior in adults that was created for use in this study.  
Participants were instructed to complete items to best describe their behavior over the past 6 
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months.  The 20-item scale rated on a 4-point scale (0 = not at all, 3 = very much) includes 8 
items based on the DSM-IV-TR criteria for Oppositional Defiant Disorder (e.g., “losing your 
temper,” “arguing with others”) and 12 items based on criteria for Conduct Disorder (e.g., 
“starting physical fights,” “deliberate fire setting”; American Psychiatric Association, 2000).  
Total scores measure symptom count (sum of items with scores of 2 or above) and severity (sum 
of items) of Oppositional Defiant Disorder and Conduct Disorder, with higher scores indicating 
higher symptom severity.  The Externalizing Behavior Rating Scale has demonstrated adequate 
internal consistency for all items (=.85) as well as for oppositional defiant disorder (=.85) and 
conduct disorder (=.66) subscales (Anastopoulos et al., 2016).  Significant correlations between 
the subscales and the CAARS ADHD Index also support the validity of this measure. 
Medication tolerability.  An oral interview about services for college students (i.e., help 
or assistance students received) included questions about participant’s medication usage.  
Participants indicated whether or not they had received medication for ADHD-related difficulties 
at any point since the start of the Fall semester.  Medications were coded as methylphenidate, 
amphetamine, non-stimulant ADHD, or other.  Participants endorsed or denied the presence of 
medication side-effects (i.e., loss of appetite, sleep disruption, irritability, other).  Affirmed side-
effects were summed to create a total side-effect score (0 to 4), with higher scores indicating 
greater numbers of side-effects.  Items on this measure also addressed the length of time that 
participants had been taking their medication (less than 1 month, 1-2 months, 3+ months), the 
prescribed frequency of administration (times per day [1 = once, 2 = twice, 3 = three or more 
times]; days per week [1 = daily, 2 = weekdays only, 3 = as needed]) of their medication, with 
higher scores indicating greater medication usage.  Participants could report up to three different 
medications utilized for ADHD-related difficulties since the start of the Fall semester.  Data for 
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this study were based on scores for medication with the highest reported usage.  The composite 
latent construct, medication tolerability, included the observed variables: total side-effects, time 
on medication, and frequency of medication usage. 
Attitude towards medication.  The composite latent construct attitude towards 
medication was comprised of scores from measures addressing knowledge about ADHD, 
perceived impairment from ADHD, and satisfaction with treatment (described below). 
Test of ADHD Knowledge (TOAK). The TOAK was created for use in this study to 
measure knowledge about ADHD.  Each of the 39 items on the scale included a statement about 
ADHD that was either true or false (e.g., “most adults with ADHD who take stimulant 
medication benefit from its use,” “taking stimulant medication for ADHD increases the risk that 
a person will use illegal drugs”).  Participants were asked to indicate whether they “agreed,” 
“disagreed,” or were “not sure” about the statement.  The total score was calculated by summing 
the total number of correct item responses to medication-related questions with higher scores 
indicating higher levels of correct knowledge.  The TOAK demonstrated adequate levels of 
internal consistency in the current sample (n=94; =.77). 
Perceived Impairment from ADHD. 
The ADHD Impact Module for Adults (AIM-A; Landgraf, 2007).  The AIM-A is a self-
report measure designed to evaluate six domains related to the quality of life for adults with 
ADHD.  Aside from the “Living with ADHD” subscale (α = .68), all domains on the AIM-A 
demonstrated adequate levels of internal consistency (α = 0.83 to 0.91).  The entire measure has 
also demonstrated adequate discriminant validity.  For the purposes of this study, Item 9B was 
utilized to collect information on the impact of ADHD symptoms on daily life.   Participants 
rated how frequently nine common symptoms of ADHD (e.g., “being distracted and jumping 
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from one activity to another,” “forgetfulness/losing things”) interfered with their daily life on a 
5-point Likert scale (1 = not at all, 5 = a lot), with higher scores indicating greater interference.  
ADHD Cognitions Test (ACT).  The ACT is a 12-item self-report scale designed to 
measure maladaptive thoughts associated with ADHD (Anastopoulos et al., manuscript in 
progress- ADHD Cognitions Scale for Adults).  Participants rate how often they experience 
various thoughts (e.g., “I’ll just do this one thing first,” “I do better waiting until the last 
minute”) on a 5-point Likert scale (1 = not at all, 5 = all the time), with higher total scores 
indicating higher rates of maladaptive thoughts associated with ADHD.  The ACT demonstrated 
adequate levels of internal consistency for the current sample (n=94, =.77). 
Satisfaction with medication.  Participants who indicated that they had received 
medication for ADHD-related difficulties at any point since the start of the Fall semester, were 
asked to indicate “in [their] opinion, how helpful was taking [name of medication]?”  Responses 
were coded on a three-point scale (1 = not very helpful, 2 = moderately helpful, 3 = very helpful). 
 Treatment Adherence.  Participants reported how closely they followed their 
medication regimen.  Answers were provided on a 3-point scale (1 = not well, 2 = moderately 
well, 3 = very well) with higher numbers indicating higher levels of treatment adherence. 
 No standard method for measuring treatment adherence has been identified in the 
previous literature, contributing to the lack of understanding and methodological limitations of 
this phenomenon (e.g., differences in time scales, changing treatments, multiple respondents; 
Emilsson et al., 2017; Osterberg & Blaschke, 2005; Quittner, Modi, Lemanek, Ievers-Landis, & 
Rapoff, 2008).  Consistent with measurement issues noted in prior studies, the limited precision 
of the identified measure of treatment adherence for the current study may provide a restricted 
understanding of this construct.  However, for the purposes of the present analysis, treatment 
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adherence was operationalized as the self-reported answer to the treatment adherence question 
described previously.  Results should therefore be interpreted according to this conceptualization 
of treatment adherence, which may be less comprehensive or discrepant from definitions used in 
other studies. 
Procedure 
 As part of the original study, each participant first underwent a screening process to 
determine group designation and eligibility for the study.  Once eligible for the study and after 
providing informed written consent, participants completed a variety of measures in a 
standardized order over a series of two or three meetings conducted by graduate students trained 
on all assessment procedures.  Data on medication tolerability, treatment satisfaction, and 
treatment adherence was collected in the final meeting (held between September-June) with all 
participants; all other data were collected in separate meetings that occurred earlier in the 
academic year.  Information on participants was derived through a combination of self-report 
ratings and interviews.  Individuals in the study were followed for four years.  Participants were 
provided with monetary incentives at the completion of each meeting and a report of their overall 
functioning for each year they participated in the study.  Only data from Year 1 will be used in 
the proposed study. 
Statistical Analysis 
Year 1 data from cohorts 1 and 2 were used to conduct analyses for the present study.  To 
better understand the relationships between latent (i.e., medication tolerability, attitudes toward 
treatment) and observed (i.e., demographic characteristics) variables and treatment adherence, 
two proposed models based on factors related to treatment adherence that were identified in the 
literature were created and tested using structural equation modeling. 
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The primary proposed model examines whether attitude towards medication mediates the 
relationship between medication tolerability and treatment adherence when controlling for 
demographic risk factors, ADHD symptom severity, and number of comorbidities (see Figure 2).  
To account for potential non-equivalent contributions of each specific demographic risk factor 
(i.e., gender, ethnicity, family history of ADHD), the second, alternative model was identical to 
the primary model; however, the composite observed variable of demographic risk factors was 
separated to individually control for gender, ethnicity, and family history of ADHD as separate 
observed variables (see Figure 3).  The model with the best fit was used to evaluate relationships 
between variables. 
Parameters of each model were estimated using the maximum likelihood procedure 
implemented in the Amos software (version 25).  In addition to the chi-square test (2), the fit 
indices used to evaluate the models were the Root Mean Square Error of Approximation 
(RMSEA), Comparative Fit Index (CFI), and Tucker Lewis Index (TLI).  A value of .05 or less 
was used to indicate good fit for the RMSEA; values of .95 or greater indicated good fit on the 
CFI, and TLI (Schumacker & Lomax, 2009). 
In order to understand whether attitudes towards medication mediates the relationship 
between medication tolerability and treatment adherence, the direct, total, and indirect effects 
between variables were examined.  According to Brown’s (1997) model, a meditational 
relationship was indicated if the following conditions were met; (a) there is a significant 
relationship between medication tolerability and treatment adherence, (b) the path between 
medication tolerability and attitudes towards medication is significant, (c) the path between 
attitudes towards medication and medication tolerability is significant, and (d) the relationship 
between medication tolerability and treatment adherence is reduced or eliminated (i.e., smaller 
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than or non-significant compared to the total-effect) when controlling for attitudes toward 
medication.  Initially, the full model was estimated to yield indirect and total effects.  
Bootstrapping was then attempted to generate the standard errors and significance tests for the 
indirect effects.  Finally, because the proposed models did not adequately fit the data, three 
separate multiple regression analyses were conducted to examine relationships between factors 
related to medication tolerability and each component of attitudes towards medication.  
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CHAPTER 3 
Results 
Prior to analyzing the specified models, the univariate normality of each observed 
variable was checked.  The skewness of all variables fell within the recommended range of -3 to 
+3 (Weston & Gore, 2006; see Table 1).  Although the kurtosis value of one variable (i.e., 
medication frequency) fell slightly outside of the recommended range of -10 to +10, given the 
acceptable skewness of all items, to improve the interpretability of the results, none of the 
variables were transformed.  Additionally, means and standard deviations of each variable were 
examined for the sample (see Table 1).  Overall, this sample of college students with ADHD was 
relatively adherent to their medication; an overwhelming majority (88.3%) of individuals 
reported that they followed their medication regimen either moderately well (37.2%) or very well 
(51.1%).   
The fit of the primary model (2[36, N=94]=57.010, p=.014, RMSEA=.079, CFI=.725, 
TLI=.580) was not acceptable according to the criteria established a priori (see Table 2 for 
individual factor loadings).  The alternative model did not converge, thus parameter estimates 
could not be obtained.  Modifications were made to the models to improve model fit 
(Schumacker & Lomax, 2010). 
Both the TOAK (knowledge) and the AIM-A (impairment) include multiple items about 
real or commonly misconceived symptoms or impacts resultant from ADHD.  For example, the 
TOAK includes items such as “many college students with ADHD display poor organizational 
skills and time management difficulties” and “college students with ADHD often have difficulty 
planning ahead and remembering things.”  The AIM-A includes items such as “forgetfulness and 
loosing things” and “being distracted and jumping from one activity to another.”  To answer 
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questions on both of these scales, individuals would be required to attribute these symptoms or 
impacts to a diagnosis of ADHD.  Therefore, it is likely that those with incorrect knowledge 
about symptoms related to ADHD may also not have attributed the symptoms addressed on the 
impairment measure to their ADHD.  Because an individual’s body of knowledge about the 
disorder very likely systematically influenced the way in which they responded to both of these 
measures, the error terms for both of these measures were correlated in the modified model.  No 
further modifications were theoretically justified or significantly improved model fit. 
Although this modified primary model (see Figure 4) represented an improvement in 
fit over the proposed primary model (p=0.009), the modified model still did not show an 
acceptable level of fit to the data according to criteria established a priori (2[35, N=94]=50.227, 
p=.046, RMSEA=.068, CFI=.801, TLI=.687).  No further modifications were theoretically 
justifiable or improved model fit.  Despite this lack of fit to established a priori criteria, given 
the small sample size, the model represented acceptable global fit according to less stringent 
standards for RMSEA values (Browne & Cudek, 1993).  The same modification was made to the 
alternative model (see Figure 5).  With the modification, the model converged and the fit of the 
alternative model was significantly improved (p=.011).  The modified alternative model also did 
not show an acceptable level of fit according to criteria established a priori (2[47, 
N=94]=71.057, p=.013, RMSEA=.074, CFI=.748, TLI=.581).  In models with sample sizes less 
than 100, RMSEA tends to worsen as the number of variables increase (Kenny & McCoach, 
2003).  Although the modified primary model and the modified alternative model showed similar 
levels of overall fit, due to the smaller number of variables included in the model, the modified 
primary model was selected for further analysis. 
When examining the fit of the model according to individual parameters, only the 
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indicators of side effects (p=.037) and thoughts about ADHD (p=.036) had statistically 
significant loadings on the latent factor to which they were assigned (see Table 3).  Values for 
the indicators of medication frequency (p=.062) and time on medication (p=.064) approached 
statistical significance, but along with of the other factor loadings in this model, did not reach 
statistical significance. Based on an assessment of both global and parameter fit, despite 
modifications to the primary model, the fit of the model was considered unacceptable. 
Although the model did not demonstrate adequate fit, to evaluate the study hypotheses, 
additional examinations were conducted on the model.  To evaluate the first hypothesis that 
examined the unique relationships of demographic risk factors, ADHD symptom severity, 
comorbidities, medication tolerability, and attitudes towards treatment with treatment adherence 
in college students with ADHD, regression weights of each variable were examined.  Contrary to 
findings in the childhood ADHD literature (Corkum et al., 2013), none of the variables were 
significantly predictive of treatment adherence in college students with ADHD. 
To examine the second hypothesis evaluating whether the latent construct of attitudes 
towards treatment mediates the relationship between the latent construct medication tolerability 
and treatment adherence when controlling for demographic risk factors, ADHD symptom 
severity, and comorbidities various relationships between the latent variables and treatment 
adherence were examined.  Contrary to the second hypothesis, however, none of the paths that 
would indicate a mediated relationship between variables were statistically significant; 
medication tolerability did not significantly predict treatment adherence (=-.628, SE=1.436, 
p=.662), medication tolerability did not significantly predict attitudes towards medication 
(=1.433, SE=.897, p=.110), and attitudes towards medication did not significantly predict 
treatment adherence (=.063, SE=.290, p=.827).  Bootstrapping analyses were not possible for 
  
45 
the current sample, likely due to the small sample size and insufficient model fit. 
Due to the insufficient model fit, and given the theoretical nature of this model and the 
paucity of research on the predictors of treatment adherence in the college age population of 
students with ADHD, additional regression analyses were conducted to further examine the 
relationship between observed variables.  Specifically, a simultaneous regression was conducted 
to determine the specific and combined relationships between each measured variable and 
treatment adherence.  None of the variables significantly predicted treatment adherence either 
individually or in combination (F[10,83]=.632, p=.782; see Table 4 for beta weights). 
Next, to further examine relationships between medication tolerability and attitudes 
towards medication, additional regression analyses were conducted.  When controlling for 
demographic risk factors, ADHD symptoms, and comorbidities, together medication side-effects, 
time on medication, and medication frequency accounted for 25.4% of the variance in perceived 
impairment from ADHD (F[6,87]=4.93, p<.001), 17.2% of the variance in satisfaction with 
treatment (F[6,87]=3.01, p=.01), and 24.7% of the variance in thoughts about ADHD 
(F[6,87]=4.76, p<.001).  These same variables did not significantly predict knowledge about 
ADHD (F[6,87]=1.95, p=.082).  Higher levels of ADHD symptoms (p<.001), less time on 
medication (p=.01), and greater medication frequency (p=.026) were significant predictors of 
higher levels of maladaptive thoughts about ADHD (see Table 5 for beta weights).  Greater time 
on medication significantly predicted greater satisfaction with medication (p<.001; Table 5).  
Lower levels of ADHD symptoms (p<.001) and fewer comorbidities (p=.05) significantly 
predicted higher perceived impairment from ADHD (see Table 5). 
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CHAPTER 4 
Discussion 
This study aimed to examine factors related to the treatment adherence of college 
students with ADHD to their prescribed pharmacological treatment.  Specifically, the present 
analysis focused on the exploration of the specific individual relationships of a variety of 
identified factors (i.e., risk factors, ADHD symptom severity, comorbidities, medication 
tolerability, and attitudes towards medication) to treatment adherence in college students with 
ADHD.  Further, this study aimed to examine whether the relationship between the latent 
construct of medication tolerability and adherence was mediated by the latent construct of 
attitudes towards treatment when controlling for other individual characteristics. 
A proposed primary model and an alternative model were tested to determine which 
model was best supported in the current sample.  The results of structural equation modeling 
maximum likelihood estimation indicated that neither model met the specified criteria to indicate 
that it was adequately supported by the data.  Because the primary model exhibited better fit than 
the alternative model, the primary model was modified and utilized for further analysis.  Even 
after theoretically justifiable modifications were made to the model; however, the model still did 
not exhibit an acceptable level of fit according to a priori criteria.  Additionally, aside from side-
effects and thoughts about ADHD, none of the indicators had statistically significant loadings on 
the latent factor to which they were assigned, indicating that the observed variables (i.e., time on 
medication, frequency of medication usage) did not accurately represent the latent variable of 
medication tolerability and that the observed variables (i.e., knowledge about ADHD, perceived 
impairment from ADHD, satisfaction with treatment) did not adequately represent the latent 
variable of attitude toward treatment.  Because of the insufficient model fit, the specific 
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hypothesized relationships could not be thoroughly explored. 
There are multiple explanations for the insufficient model fit in this sample.  The 
psychometric properties of the observed variables selected for use in this study have not been 
examined with respect to their ability to adequately measure the constructs of interest identified 
in this study (i.e., factors related to treatment adherence).  For this reason, despite the 
psychometric adequacy of the measure for other purposes, the utilization of these instruments in 
the current study may have led to insufficient measurement of the identified constructs.  Certain 
measures (e.g., TOAK, ACT) were created for use in this study, and demonstrated sufficient, but 
moderate reliability in the current sample.  Additionally, many of the observed variables were 
measured through a single item (e.g., time on medication, and frequency of medication usage) or 
a portion of a full measure (e.g., perceived impairment items).  These alterations to the intended 
and validated use of these measurement tools may have limited the reliability and validity of the 
measurement of the variables of interest.  Based on the trend towards statistical significance of 
all variables assigned to the latent factor medication tolerability, it is likely that more extensive 
measurements were necessary to adequately capture this latent construct. 
It is also possible that the groupings of observed variables were not conceptually similar 
enough to accurately create the defined latent variables.  Although, based on the literature, the 
grouped observed variables appear to measure similar constructs, it is possible that variables 
such as knowledge about ADHD and perceived impairment from ADHD, for example, may 
measure dissimilar constructs that would be more appropriately captured through a different 
conceptualization of latent variables.   
It is also critical to consider the influence of the study’s small sample size on the overall 
model fit.  Although Schumacker and Lomax (2010) indicate the possibility of conducting a 
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structural equation model with 100 participants, typical recommendations require the inclusion 
of a minimum of 200 participants for this type of analysis.  Because college students with ADHD 
who are taking medication are a difficult population to access, it was decided that the sample size 
for the present study was acceptable to perform the analysis; however, guidelines for model fit in 
samples with fewer than 100 participants are extremely limited and may not conform to the 
typical expectations for model fit with larger samples (MacCallum & Austin, 2000).  Given the 
sensitivity of measures of fit to sample size, smaller sample sizes can impair the ability to 
accurately generate and interpret results of structural equation modeling procedures.  For these 
reasons, additional analyses with larger samples are necessary to more sufficiently determine the 
representativeness of these findings for the larger population of college students with ADHD. 
The global fit of the modified proposed model may be considered acceptable according to 
less stringent criteria than had been determined a priori.  For example, Browne and Cudeck 
(1993) cite RMSEA values between 0.06 and 0.08 as acceptable.  Given the small sample size, 
together with the non-significant 2 value, it may be plausible to designate the global fit of the 
model as an adequate representation of the current sample.  Although there is limited guidance 
available on the appropriateness of the use of various fit indices for non-continuous data, 
Garrido, Abad, and Ponsoda (2016) suggest that RMSEA, CFI, and TLI perform similarly for use 
with unskewed categorical variables.  In comparison with the other fit indices, however, RMSEA 
can provide more accurate and descriptive information in small sample sizes (Smith & 
McMillan, 2001).  Therefore, based on the small sample size and use of categorical variables in 
the analysis, judgment of fit was weighted more strongly on RMSEA than the other fit indices. 
Despite this allowance, however, the results generated from the model did not support the 
hypotheses.  Specifically, no statistically significant relationships between identified factors (i.e., 
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risk factors, ADHD symptom severity, comorbidities, medication tolerability, and attitudes 
towards medication) and treatment adherence in college students with ADHD were identified.  
Additionally, there were no statistically significant relationships between medication tolerability 
and treatment adherence, medication tolerability and attitudes towards treatment, or attitudes 
towards treatment and treatment adherence.  These non-significant relationships contradict the 
hypothesis that attitudes towards treatment mediated the relationship between medication 
tolerability and treatment adherence.  Further, regardless of the acceptability of model fit, 
additional findings from a multiple regression analysis corroborate the non-significant findings 
of the relationships between individual identified factors and treatment adherence.  None of the 
observed variables predicted treatment adherence, either in isolation or in combination. 
Because of the small sample size and lack of model fit, additional regression analyses 
were conducted to more thoroughly examine relationships between factors related to medication 
tolerability and attitudes towards treatment.  When controlling for individual characteristics, 
factors related to medication tolerability were significantly predictive of various components of 
attitudes towards treatment (i.e., perceived impairment from ADHD, treatment satisfaction, 
thoughts about ADHD).  These results suggest that the measures used within the present study 
for measuring attitudes towards treatment may not have been sufficiently detailed or 
psychometrically strong enough to demonstrate adequate measurement of the latent variable in 
the current sample.  Based on the results of these specific predictive relationships, it is likely that 
utilizing measures that more accurately, consistently, and reliably measure this construct may 
provide a stronger conceptualization of attitudes towards treatment.  For example, instruments 
that measure multiple aspects of the perceived risks and benefits of ADHD medication use in 
greater detail would likely provide a more valid operationalization of this construct.  Further, 
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particularly because the TOAK only included 3 items that were specifically focused on 
medication, an alternative measure of ADHD knowledge with a greater focus on potential risks 
and benefits of psychopharmacological treatment may be more appropriate for indicating 
attitudes towards treatment.  
These specific relationships between factors related to medication tolerability and 
individual aspects of attitudes towards treatment (i.e., perceived impairment from ADHD, 
treatment satisfaction, thoughts about ADHD), however, are supported by previous research that 
indicates the influence of medication tolerability on the perceived risks and benefits of treatment 
use, an important component of attitudes towards treatment (Horne & Weinman, 1999).  Higher 
levels of ADHD symptoms, less time on medication, and greater medication frequency were 
significant predictors of higher levels of maladaptive thoughts about ADHD.  These relationships 
are consistent with past literature that has identified higher symptom severity (Ahmed & Aslani, 
2013; Atzori et al., 2009) and difficulty of taking medication (Christensen et al., 2010) as related 
to adherence.  Presumably, individuals with greater symptom severity who also have more 
challenging and novel medication regimens may experience more negative thoughts about their 
condition and condition management.  Additionally, individuals who perceive treatment benefits 
and believe in the effectiveness of their treatment are likely to maintain their treatment over time 
(Charach & Fernandez, 2013; Wong et al., 2009).  Therefore, it is also not surprising that greater 
time on medication predicted greater satisfaction with treatment.  Although not explicitely 
examined, for similar reasons, the significant correlation between these two variables likely 
supports a bidirectional relationship. 
Unexpectedly, lower levels of symptom severity and fewer comorbidities significantly 
predicted higher levels of perceived impairment from ADHD.  It is possible that those with less 
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severe symptoms have less intense treatment regimens than those with greater overall symptom 
severity.  As a result, despite their less severe symptomatology, these individuals may not be as 
well managed on treatment; and therefore, perceive greater impairment from their symptoms.  
For comorbid diagnoses in particular, there are mixed findings on how these symptoms impact 
the attitudes and treatment adherence of individuals with ADHD (Atzori et al., 2009; Charach et 
al., 2004; Corkum et al., 2015; Palli et al., 2012; Thiruchevlam et al., 2001).  These relationships 
warrant further exploration in future research to more clearly understand the impacts of symptom 
severity and comorbidities on attitudes towards treatment. 
Another surprising finding was the lack of statistically significant relationships between 
factors related to medication tolerability and knowledge about ADHD.  Theoretically, those with 
greater knowledge about the uses and benefits of psychopharmacological interventions would 
perceive their own medication as more beneficial (Charach & Fernandez, 2013).  However, to 
date, there is no research that indicates the specific body of knowledge necessary to improve 
attitudes related to medication use.  Particularly because only 2 out of 39 questions on the 
knowledge measure used in this study focused on the potential benefits of medication use for 
ADHD, it is possible that the knowledge assessed in this study did not include information 
necessary for promoting more positive attitudes towards treatment. 
Because of the deficit of prior research on treatment adherence in the college population, 
the analyses in the present study were largely exploratory in nature.  Overall, the individuals in 
this study had relatively high rates of treatment adherence to their ADHD medication, limiting 
the variability of adherence rates reported in the study and, therefore, possibly obscuring the 
predicted relationships within the sample.  However, because college students represent such a 
unique facet of the population of individuals with ADHD, the treatment adherence patterns of 
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college students may be different than those of the rest of the population.  Therefore, factors 
identified for the childhood population may not influence treatment adherence in this population 
or for adults in general.  Due to the significant, well documented, decline in adherence rates 
during emerging adulthood, it is possible that those who are taking ADHD medication during 
their first year of college are either not strongly experiencing factors that negatively impact 
treatment adherence or have experienced higher rates of benefits than risks from taking their 
ADHD medication, a critical factor in treatment adherence (Adler et al., 2010; Corkum et al., 
1999; Faraone et al., 2007; Gau et al., 2008; Marcus et al., 2005; Thiruchelvam et al., 2001).  
These non-significant relationships in combination with moderate to high rates of treatment 
adherence in this sample, lend support for the existence of differences between the general 
population of individuals with ADHD and college students with ADHD in terms of medication 
tolerability and attitudes towards treatment.  These differences, if identified, may provide 
important strategies that can inform interventions to support treatment adherence in the general 
population of individuals with ADHD. 
The transition to the college environment includes unique challenges that can impact 
treatment adherence.  In addition to the increased emphasis on self-regulation (Fleming & 
McMahon, 2012), the class schedules of college students are typically difference from the 
traditional high school schedule.  The irregularity of class days and times throughout the week 
might necessitate alterations in medical regimens.  For example, a student with a full day of 
classes on Monday, might only have a single class on Tuesday afternoon.  Day-to-day variability 
in medication regimens may be necessary to promote optimal functioning within the context of 
these irregular schedules (e.g., short vs. long acting medications; administration at different 
points during the day).  These potential inconsistencies with and alterations to medication 
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routines may make treatment adherence more difficult for college students.  Additionally, 
measurement of treatment adherence under these conditions may be confounded, which may 
have impacted the results of this study.  Measurement of treatment adherence in the college 
environment presents particular challenges that may necessitate specific methodological 
considerations in future studies (e.g., assessment of variable medication routines). 
Although it appears that for this population, medication tolerability and individual 
characteristics are, at least in part, related to various components of attitudes towards medication, 
the links between attitudes towards treatment and treatment adherence are less clear.  Particularly 
given the results of follow-up regression analyses, it is possible that the latent variables 
conceptualized in this model and measure of treatment adherence utilized in this study were 
insufficient for use in accurately exploring these relationships.  The lack of information on 
factors related to treatment adherence in adults makes it difficult to contextualize and understand 
the accuracy or generalizability of these results to other portions of this population (e.g., there is 
no current information on whether or not these identified factors influence the general adult 
population with ADHD).  Further, there is no clear estimate of treatment adherence rates across 
different facets of the adult population.  The limited information available suggests that factors 
influencing treatment adherence, medication tolerability, and attitudes towards treatment in 
college students are likely different from those of the rest of the population of individuals with 
ADHD (e.g., children, other adults), To thoroughly understand differences between the college 
population and other subsets of the population with ADHD, more research with greater 
methodological control is necessary. 
Limitations 
Findings from the current study should be interpreted in light of its limitations.  One of 
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the main methodological difficulties cited in the adherence literature in general is the lack of 
standardization in the definitions and measurements of treatment adherence (Emilsson et al., 
2017; Osterberg & Blaschke, 2005).  In the present study, treatment adherence was 
operationalized according to a response to a single item (i.e., “how closely did you follow [your] 
medication regimen”).  As mentioned previously, treatment adherence is generally 
conceptualized as the extent to which a person’s behavior follows the agreed upon 
recommendations from the health care provider (e.g., dose, frequency, duration; Sabate, 2003; 
Treuer et al., 2016).  The measurement utilized in the present analysis may have provided an 
oversimplified definition of treatment adherence that is inconsistent with alternative definitions.  
Additionally, the 3-point scale limited the variability of responses, providing a restricted range 
for the measurement of treatment adherence.  The use of a single categorical outcome variable, 
versus the use of more items with continuous data, may have also limited the value of SEM for 
use in this study (Garrido et al., 2016).  A more extensive measure of treatment adherence may 
have allowed for a more accurate and thorough representation of the construct. 
Treatment adherence is a complicated construct that should be viewed on a spectrum 
rather than categorically (i.e., non adherent vs. adherent).  For example, individuals who use their 
medication as prescribed 50% of the time may have different characteristics than individuals 
who use their medication as prescribed 75% of the time, or than individuals who incorrectly use 
their medication 100% of the time (e.g., incorrect dosage or administration).  A measure with 
multiple subscales that provides a more descriptive range of components of treatment adherence 
(e.g., understanding of treatment, perceived frequency of use, intensity of treatment) could be 
useful in detecting these idiosyncratic differences.  More descriptive measurements would be 
useful in providing more accurate information that would promote a better understanding about 
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the various components of treatment adherence that could be differentially impacted based on 
attitudes towards treatment, medication tolerability, and individual characteristics.  This 
information would also be helpful in understanding current rates of treatment adherence and 
creating a definition of treatment adherence that is most useful and informative both in research 
and clinical practice. 
To qualify for inclusion in the present study, participants needed to have indicated that 
they had used medication for ADHD-related difficulties at any point since the beginning of the 
Fall semester.  As a result, the sample did not capture data on individuals who had been 
prescribed medication that either terminated or did not utilize their prescribed treatments at all.  
For this reason, at baseline, participants in this sample may have displayed higher rates of 
adherence than the rest of the population.  Because the individuals in this sample had continued, 
to some degree, to utilize their pharmacological treatments in college, their attitudes towards 
treatment and other factors related to treatment adherence may have differed (i.e., more positive) 
from those of the individuals who did not utilize their treatment who were not included in this 
analysis.  Obtaining a sample without this inherent bias would provide a fuller picture of 
treatment adherence patterns and factors related to treatment adherence in this population. 
The small sample size and insufficiency of the model fit according to a priori 
specifications also limited the ability to analyze the study hypotheses.  Additionally, the 
psychometric properties of many of the measurement tools interfered with the interpretation and 
accuracy of the results.  Despite these limitations, however, the proposed model may still be 
considered acceptable according to less stringent criteria that may be more appropriate with a 
smaller sample size.  Similar methodology should be replicated in a larger sample to lead to 
more firm conclusions about treatment adherence in this population. 
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Access to and the quality of services may have been impacted by the socioeconomic 
status (SES) of participants.  The SES of individuals in the current sample was not reported or 
controlled for in the analysis, possible further limiting the generalizability of results.  
Additionally, because this study was non-interventional, there was no control over variations in 
treatment type and intensity across participants.  Factors related to treatment adherence can differ 
based on treatment type, and therefore, this variability diminished control within the study 
(Christensen et al., 2010; Gajria et al., 2014).  However, given the lack of standardization in 
treatment across the population, the applied nature of this research is more generalizable to help 
inform interventions for a larger portion of individuals with ADHD.  Another limitation to this 
study concerns the time frame of data collection.  Data were collected throughout the academic 
year.  The time of year that the assessment took place may have impacted adherence patterns 
(e.g., students who reported on their treatment adherence early on in the semester may have 
higher or lower reports of adherence than those assessed later in the school year).  Further, data 
for this study only examined treatment adherence during the first year of college.  Rates of 
treatment adherence tend to increase after the first year of college (Gray et al., 2018).  The lack 
of standardization in the time of year that the data were collected as well as the limited time 
frame (i.e., year 1 of college) may have confounded the results and limited the generalizability of 
obtained findings to other college students. 
Additionally, because many measures relied on self-report data, there is a lack of 
objective understanding of many of the constructs.  For a topic such as treatment adherence, for 
example, people may unintentionally overestimate or misrepresent their actual rates of adherence 
(e.g., due to social desirability or memory bias; Wilson, Carter, & Berg, 2009).  Both objective 
and subjective methods of reporting on treatment adherence represent unique challenges and 
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advantages for obtaining data (Chesney, 2006; Garfield, Clifford, Eliasson, Barber, & Willson, 
2011; Quittner et al., 2008; Williams, Amico, Boya, & Womack, 2013) and may vary in 
accuracy and utility across different chronic conditions (Stirratt et al., 2015).  To obtain the most 
accurate estimation, extensive data collected through multiple methods (e.g., objective data, daily 
pill counts, treatment diary, multiple informants should be included to corroborate self-report. 
Future Directions 
Inconclusive findings from this study highlight the problematic nature of the dearth of 
information on treatment adherence for individuals with ADHD.  Results from this study 
contradict findings from past studies and suggest that the factors most strongly related to 
treatment adherence in childhood are likely different from those in adulthood.  Continuing to 
examine factors related to treatment adherence for emerging adults with ADHD may help to 
improve treatment adherence within this population as well as with other populations of 
individuals with various chronic illnesses.  Exploring factors related to treatment adherence in 
larger samples across different subsets (e.g., varying ages, socioeconomic status, education 
levels) of the population with ADHD is critical to maximize outcomes for these individuals.  
Consistent with the developmental model, a greater understanding of barriers and benefits to 
treatment across the lifespan and individual circumstances will provide important information to 
design and implement appropriate interventions that promote medication use (Sibley et al., 
2014).  Utilizing measures with strong psychometric properties that thoroughly and accurately 
capture the constructs of medication tolerability, attitudes towards treatment, and treatment 
adherence will provide important information on both the alterable and inalterable factors related 
to treatment adherence for individuals with ADHD.  For example, a measure that specifically 
assesses knowledge of ADHD medication would be particularly important to better understand 
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the relationship between knowledge and treatment adherence. 
As research on treatment adherence continues to expand, it is also critical to obtain a 
more accurate estimate of adherence rates across various subsets of the population of individuals 
with ADHD (e.g., children, college students, adults) to help illuminate differences across the 
lifespan that can aid in targeting effective and appropriate interventions.  Additionally, if college 
students do, in fact, have higher adherence rates than the rest of the population, characteristics of 
this population can be carefully examined to further inform interventional techniques that will 
promote adherence for other individuals.   
Future studies should also examine differences between college students with ADHD 
who are prescribed medication and those who are not.  Because treatment adherence declines 
over the lifespan, particularly during emerging adulthood, there are likely differences between 
individuals who continue to take their medication in college and those who do not (Ahmed & 
Aslani, 2013; Barkley et al., 2001; Bussing et al., 2012; Charach & Fernandez, 2013).  Further, it 
would be interesting to examine changes in treatment adherence before, during, and after college 
to identify environmental contributions to treatment adherence. 
This study concentrated on treatment adherence to psychopharmacological interventions 
for ADHD.  To continue to address gaps in the current literature, future research should also 
examine factors related to treatment adherence to psychosocial interventions.  For example, 
examining the ways that various aspects (e.g., type, dosage, sustainable effects) of psychosocial 
treatments or combined treatments impact adherence throughout the lifespan will further 
illuminate differences in adherence patterns to better inform treatment for ADHD.  Based on the 
unique risks and benefits of each treatment type, it is likely that factors related to adherence may 
vary significantly across treatments.  It is also possible that unmeasured effects of psychosocial 
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interventions contribute to adherence rates of psychopharmacological interventions (e.g., 
development of self-regulation strategies decreasing need for medication overtime).  More 
information on adherence to psychosocial treatments may help inform healthcare providers in 
their recommendations to provide best practice, sustainable treatment options.  Additionally, to 
rectify methodological limitations in the adherence research, it is necessary to identify a 
standardized definition and measure of treatment adherence that can be used throughout the 
literature. 
Conclusions 
In general, there is limited information on factors related to treatment adherence, 
particularly in the emerging adult population (Ahmed & Aslani, 2013; Gajria et al., 2014).  
Although there is support for the contribution of a combination of a variety of factors (e.g., 
individual characteristics, medication tolerability) to rates of treatment adherence to 
psychopharmacological treatments in the pediatric population, the individual contributions of 
each unique factor had previously remained unstudied (Corkum et al., 2013).  Contrary to past 
literature, according to the results of this study, none of the previously identified factors were 
significantly predictive of treatment adherence in college students with ADHD either 
individually or in combination.  Although these results may be partially due to statistical 
limitations, these contradictions with the extant literature further necessitate the critical need for 
additional research in this area to best identify areas of intervention that can maximize outcomes 
for these individuals.  Adherence is largely related to the degree to which an individual’s belief 
in the necessity of treatment overrides the individual’s concern about treatment risks (Emilsson 
et al., 2017).  Based on the results of this study, it is possible that these perceived risks and 
benefits are different for the college population, and are impacting treatment use.  A greater 
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understanding of factors that influence these perceptions is necessary to promote adherence to 
psychopharmacological treatments in this population as well as to provide important information 
that may help to improve outcomes for all individuals with ADHD. 
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Note. * Correlation is significant at the p.05 level 
**Correlation is significant at the p.01 level
Table 1. Correlations, Means, SDs, Skewness, and Kurtosis Values for Full Group 
Variable 
Risk 
Factors 
ADHD Sx Comorbidities 
Side 
Effects 
Time on 
Meds. 
Med. 
Frequency 
Knowledge Impairment Satisfaction Thoughts 
Tx. 
Adherence 
Risk 
Factors 
1           
ADHD Sx -.086 1          
Comorbidities -.237* .289** 1         
Side 
Effects 
-.083 .196 .215* 1        
Time on 
Meds. 
-.026 .220** -.002 .115 1       
Med. 
Frequency 
.044 .175 -.051 .089 .139 1      
Knowledge -.059 .310** .112 -.058 .120 .067 1     
Impairment .092 -.455** -.317** -.170 -.103 -.142 .006 1    
Satisfaction .102 -.028 .046 .129 .349** -.038 .045 .053 1   
Thoughts -.029 .367** -.012 .028 -.131 .259* .150 -.337** -.131 1  
Tx 
Adherence 
-.078 .061 -.069 -.025 .050 -.101 .082 .040 .069 -.127 1 
            
M 1.18 10.74 0.94 1.56 2.82 6.55 21.06 56.60 2.63 35.79 2.39 
SD 0.73 3.68 1.05 1.17 0.53 2.54 5.46 20.10 0.62 7.72 0.07 
Skewness 0.04 0.19 1.05 0.50 -2.87 2.71 0.34 -0.43 -1.73 0.07 -0.71 
Kurtosis -0.47 -0.90 0.66 -0.42 6.94 11.79 0.01 -0.11 3.09 -0.07 -0.65 
   
90 
 
Table 2. Regression Weights for the Primary Model 
 Medication Tolerability Attitudes Towards Medication 
  B SE B  B SE B 
Side Effects .231* .268* .133 -- -- -- 
Time on Medication .208 .109 .060 -- -- -- 
Medication Frequency .222 .562 289 -- -- -- 
Knowledge -- -- -- .294 .571 .904 
Impairment -- -- -- -.555 -3.974 6.214 
Satisfaction -- -- -- -.052 -.012 .031 
Thoughts -- -- -- .463 1.274 1.990 
Note. *Regression values significant at p.05 level 
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Table 3. Regression Weights for the Modified Primary Model 
 Medication Tolerability Attitudes Towards Medication 
  B SE B  B SE B 
Side Effects .238* .277* .133 -- -- -- 
Time on Medication .211 .111  .060 -- -- -- 
Medication Frequency .212 .537 .288 -- -- -- 
Knowledge -- -- -- .383 1.192 .693 
Impairment -- -- -- -.670 -7.663 3.883 
Satisfaction -- -- -- -.048 -.017 .043 
Thoughts -- -- -- .478* 2.101* 1.001 
Note. *Regression values significant at p.05 level 
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Table 4. Regression Analysis of Predictors of Treatment Adherence 
 
 
 B SE B 
Risk Factors -.109 -.103 .104 
ADHD Symptoms .166 .031 .026 
Comorbidities -.160 -.105 .081 
Side Effects -.023 -.014 .066 
Time on Medication -.036 -.048 .161 
Medication Frequency -.083 -.023 .031 
Knowledge .074 .009 .015 
Impairment -.010 .000 .004 
Satisfaction .079 .088 .130 
Thoughts -.180 -.016 .011 
Note. All regression values are non-significant at p.05 level 
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Table 5. Regression Analysis of Predictors of Variables Related to Attitudes Towards Treatment 
 
 
Knowledge Impairment Satisfaction Thoughts 
 
 B SE B  B SE B  B SE B b B SE B 
Risk Factors -.033 -.244 .773 .012 .336 2.621 .134 .114 .085 -.041 -.434 1.012 
ADHD Symptoms .302 .449 .164 -.371 -2.026 .555 -.134 -.023 .018 .423 .888 .214 
Comorbidities .048 .249 .576 -.202 -3.880 1.950 .089 .053 .064 -.129 -.955 .753 
Side Effects -.140 -.652 .490 -.044 -.765 1.659 .111 .059 .054 -.021 -.142 .640 
Time on Medication .066 .678 1.079 -.005 -.183 3.655 .381 .448 .119 -.253 -3.699 1.411 
Medication Frequency .021 .046 .223 -.084 -.660 .754 -.079 -.019 .025 .217 .660 .291 
Note. Standard Error reported in parentheses 
         *Beta weight significant at p.05 level 
         **Beta weight significant at p.001 level 
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Figure 1. Sampling Information 
 
 
 
Total Sample of 
Participants with ADHD
(N=204)
Endorsed Use of 
Medication
(n=99)
Complete Data
(n=94)
Final Analysis Sample 
(n=94)
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Figure 2. Primary proposed mediation model.
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Figure 3. Alternative proposed mediation model. 
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Figure 4. Modified primary mediation model. 
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Figure 5. Modified alternative mediation model.
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